How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• Typical: many people lose roughly 5–15% of body weight in the first 6–12 months on prescription GLP‑1s; some drugs and doses produce larger losses (see below).
• Long‑term: GLP‑1s suppress appetite and change energy intake while you take them, so most people regain weight if the drug is stopped unless they keep durable lifestyle/behavior changes or continue treatment. In other words: effective while used, but usually not a one‑time “cure.”

How fast you’ll lose weight (typical ranges)

• Semaglutide (Wegovy 2.4 mg, the dose approved for obesity): average ≈10–15% body‑weight loss over ~68 weeks in clinical trials. Many people see noticeable losses in the first 3 months (often several percent).
• Tirzepatide (Zepbound for weight; tirzepatide was studied as Mounjaro for diabetes): trials showed larger average losses — often in the ~15–20% range over ~72 weeks, with the highest doses producing mean losses >20% in some studies.
• Ozempic (semaglutide for diabetes) and Rybelsus (oral semaglutide): are diabetes drugs that are sometimes used off‑label for weight; Ozempic’s injection at diabetes doses gives meaningful loss but less than the approved Wegovy dose.
  These are averages — individual results vary a lot depending on starting weight, dose, diet, activity, adherence, side effects, and biology.

Why weight often slows or returns

• The body adapts: appetite hormones, metabolism, and reward pathways change in response to weight loss — GLP‑1s blunt appetite but stopping them usually lets appetite rebound.
• Unless behavioral changes are firmly established (diet habits, activity, environment, coping strategies), stopping medication commonly leads to regain. Some people need long‑term treatment to maintain the loss.

Safety and practical issues

• Common side effects: nausea, constipation, diarrhea, abdominal pain — often improve over weeks.
• Important cautions: history of pancreatitis, personal/family history of medullary thyroid carcinoma or MEN2, pregnancy/planning pregnancy are important contraindications/considerations.
• You need medical supervision: baseline labs, monitoring, dose titration, and follow‑up for side effects and efficacy.

What to do next (actionable)

1. Talk to your primary care clinician or an obesity medicine specialist to see whether a GLP‑1 is appropriate for you and which agent/dose fits your situation.
2. Expect a plan that includes dose titration, lifestyle support (nutrition and behavior), and periodic reassessment (usually every few months).
3. If cost/access is an issue, check insurance coverage and patient‑support programs from the manufacturer.

Brands and services (specific recommendations)

• Wegovy (semaglutide) — FDA‑approved for chronic weight management; good evidence and structured dosing for obesity.
• Zepbound (tirzepatide) — FDA‑approved tirzepatide for weight management; showed larger average losses in trials.
• Ozempic (semaglutide) / Mounjaro (tirzepatide) — diabetes brands by Novo Nordisk and Eli Lilly respectively; sometimes used under clinician guidance (different labeling/doses).
• Obesity Medicine Association (find an obesity medicine specialist) — specialists trained in medication‑assisted weight care and comprehensive management.
• Major multidisciplinary centers (examples): Mayo Clinic Weight Management Center, Cleveland Clinic Bariatric & Metabolic Institute — offer dietitians, behavioral therapy, endocrinology/bariatrics and long‑term follow up.
• Telehealth clinics (examples): Ro, Hims & Hers, or local accredited weight‑management telemedicine programs — convenient for follow‑up and prescriptions, but verify that they provide medical oversight and behavioral support.

Bottom line GLP‑1 medications can produce substantial weight loss (commonly 10% or more over a year; some drugs/doses produce 15–20% or greater). They’re most effective as part of a structured plan (medical supervision + lifestyle/behavior changes). If you stop the drug, weight regain is common — so sustainability usually requires either ongoing medication or strong, sustained behavioral change and follow‑up.

If you’d like, tell me:

• your approximate BMI or starting weight and any medical conditions, and I can summarize which agents are most likely appropriate and what to expect for your situation.